CYTKCytokinetics, Incorporated
Price
+29%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality strong, hard red flags, growth steady, the market undecided.
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Cytokinetics, Incorporated (CYTK) reported revenue of $29M in Q2 2026 (quarter ended Jun 30, 2026), down 57% from the same quarter a year earlier. That came with net loss of $199M. For the full year FY2025, revenue was $88M (+377% year on year) and net income −$785M. Its largest product in Q2 2026 was Net Product at $25M, 89% of the disclosed total, well ahead of Collaboration at 11%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 28, 2026On August 28, 2026, Cytokinetics, Incorporated issued a press release announcing its presentation of the full results of ACACIA-HCM at the European Society of Cardiology (ESC) Congress 2026 and published in the New England Journal of Medicine.Other event · Form 8-K
- Aug 13, 2026On August 13, 2026, Cytokinetics, Incorporated (the “Company”) filed a complaint in the United States District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The complaint seeks a declaratory judgment that the Company does not infringe U.S. Patent No. 12,616,697 (the “’697 …Other event · Form 8-K
- Aug 6, 2026Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $28.6MThe company’s own SEC segment disclosure.
- Net Product$25.3M89%
- Collaboration$3.3M11%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.